3 Amendments of Geert BOURGEOIS related to 2020/2071(INI)
Amendment 20 #
Draft opinion
Paragraph 2
Paragraph 2
2. Recognises that the EU depends on a narrow set of countries for a large proportion of its imports of low technology medical supplies, active pharmaceutical ingredients and chemical raw materials; stresses that this over- reliance can pose a risk when limitations in production capacity, excess demand or protectionist measures threaten the proper functioning of global supply chains and potentially undermine the availability of medicines in the EU; calls on the Commission to present a long-term strategy focused on ensuring the EU’s open strategic autonomy in health;
Amendment 30 #
Draft opinion
Paragraph 3
Paragraph 3
3. Emphasises that the EU is a leading global exporter of pharmaceutical products and one of the most research intensive region in this area in the world; notes that the protection and enforcement of IP rights in free trade agreements (FTAs) and at the WTO is crucial to the development of new medicines and treatments; underlines that the flexibilities provided in the TRIPS agreement can be used to address potential supply shortages in exceptional circumstances;
Amendment 56 #
Draft opinion
Paragraph 6
Paragraph 6
6. Underlines that a complete repatriation of medical supply chains is noteither possible in a global economyor desirable as global medical markets and global specialisation is to the benefit of the EU; urges the Commission and the Member States to work with the EU’s partners, the WHO and WTO, on establishing an international framework that can prevent the breakdown of supply chains and limit resort to protectionist measures during health crises.